subjects are still lacking. Anti-FVIII inhibitory antibodies once generated sustain for very long time due to the persistence of memory B cells. We devised and investigated single or combination therapy using agents targeting memory B cells to eradicate/inactivate the memory responses and agents inducing Treg expansion to suppress the T cell function. A monoclonal anti-murine CD20 IgG2a antibody was used to deplete pan B lymphocytes from pre-B cells to memory B cells ranged from 50-80%. The depletion of B cells lasted for sustained periods of time and gradually returned to normal at ∼8 weeks post treatment. A specifi c IL2/IL2mAb (JES6-1) complex was used to induce in vivo expansion of Treg cells. Treg cells increased ∼5-7 folds in the peak day (day 3 post treatment), then gradually returned to normal levels at 9-12 days following treatment. Rapamycin was used to enhance and maintain Treg cell expansion. Inhibitor mice were generated by hydrodynamic injection of 50 µg of hFVIII plasmid via tail vein of hemophilia A mice and only mice with inhibitor titers >30 Bethesda units were used. Five groups of FVIII plasmid-primed inhibitor mice were treated with fi ve different immunomodualtion regimens: anti-CD20+IL2/IL2mAb complexes+rapamycin+FVIII, anti CD20+IL2/IL2mAb complexes+rapamycin, anti-CD20+FVIII, IL2/IL2mAb complexes+rapamycin+FVIII, FVIII+IgG control. Anti-CD20 (250 µg/mouse/treatment) was given i.v. 3 times in consecutive days at the fi rst week, followed by a second boost at the third week. IL2/IL2 mAb complexes (6 ug/mouse) and rapamycin (25 ug/mouse) were injected i.p. for three consecutive days every week for 4 weeks. FVIII protein (0.3U/mouse) was given 3 times every other day per week for 4 weeks. Combination therapy used the same schedule for each agent as the single treatment. Except the FVIII+IgG control group, all four groups treated with immunosuppressive regimens showed a reduction of inhibitory titers following treatment. Most signifi cant reduction of inhibitory antibody titers was detected in the anti-CD20+IL2/IL2mAb complex+rapamycin+FVIII treated group, inhibitor titer was reduced to 0 in two out of the four treated mice and a reversion of 8% FVIII gene expression was observed. Long-term responses are being followed and second challenge with FVIII plasmid will be used to evaluate the induction of long term tolerance to FVIII. These combination regimens are highly promising in modulating/eliminating pre-existing anti-FVIII antibodies and inducing long-term tolerance in FVIII plasmid primed subjects.
subjects are still lacking. Anti-FVIII inhibitory antibodies once generated sustain for very long time due to the persistence of memory B cells. We devised and investigated single or combination therapy using agents targeting memory B cells to eradicate/inactivate the memory responses and agents inducing Treg expansion to suppress the T cell function. A monoclonal anti-murine CD20 IgG2a antibody was used to deplete pan B lymphocytes from pre-B cells to memory B cells ranged from 50-80%. The depletion of B cells lasted for sustained periods of time and gradually returned to normal at ∼8 weeks post treatment. A specifi c IL2/IL2mAb (JES6-1) complex was used to induce in vivo expansion of Treg cells. Treg cells increased ∼5-7 folds in the peak day (day 3 post treatment), then gradually returned to normal levels at 9-12 days following treatment. Rapamycin was used to enhance and maintain Treg cell expansion. Inhibitor mice were generated by hydrodynamic injection of 50 µg of hFVIII plasmid via tail vein of hemophilia A mice and only mice with inhibitor titers >30 Bethesda units were used. Five groups of FVIII plasmid-primed inhibitor mice were treated with fi ve different immunomodualtion regimens: anti-CD20+IL2/IL2mAb complexes+rapamycin+FVIII, anti CD20+IL2/IL2mAb complexes+rapamycin, anti-CD20+FVIII, IL2/IL2mAb complexes+rapamycin+FVIII, FVIII+IgG control. Anti-CD20 (250 µg/mouse/treatment) was given i.v. 3 times in consecutive days at the fi rst week, followed by a second boost at the third week. IL2/IL2 mAb complexes (6 ug/mouse) and rapamycin (25 ug/mouse) were injected i.p. for three consecutive days every week for 4 weeks. FVIII protein (0.3U/mouse) was given 3 times every other day per week for 4 weeks. Combination therapy used the same schedule for each agent as the single treatment. Except the FVIII+IgG control group, all four groups treated with immunosuppressive regimens showed a reduction of inhibitory titers following treatment. Most signifi cant reduction of inhibitory antibody titers was detected in the anti-CD20+IL2/IL2mAb complex+rapamycin+FVIII treated group, inhibitor titer was reduced to 0 in two out of the four treated mice and a reversion of 8% FVIII gene expression was observed. Long-term responses are being followed and second challenge with FVIII plasmid will be used to evaluate the induction of long term tolerance to FVIII. These combination regimens are highly promising in modulating/eliminating pre-existing anti-FVIII antibodies and inducing long-term tolerance in FVIII plasmid primed subjects. Although preclinical results with oncolytic adenoviruses have been promising, and clinical safety has been excellent, it is also apparent that tumors can become virus resistant resulting in progression after initial response. The resistance mechanisms acquired by advanced tumors against conventional therapies are increasingly well-understood, which has allowed designing countermeasures. To study this in the context of oncolytic adenovirus, we developed an in vivo model of acquired resistance, and investigated the phenomenon on the RNA and protein levels using two types of analysis of microarray data, reverse transcriptase-polymerase chain reaction and immunohistochemistry. Interferon signaling pathways were found upregulated and Myxovirus resistance protein A expression was identifi ed as a simple marker protein correlating with resistance to virus. Furthermore, pathway analysis suggested potential therapeutic targets to counteract interferon induction. Improved understanding of the antiviral phenotype causing tumor recurrence is of key importance in order to improve treatment of advanced tumors with oncolytic adenoviruses. We identifi ed upregulated interferon signaling as an in vivo resistance mechanism that tumors can acquire to escape the antitumor effect of oncolytic adenovirus. Given the similarities between mechanisms of action, this fi nding might be relevant for other oncolytic viruses as well.
Upregulation of Interferon Pathways in Tumors Resistant to Oncolytic Adenovirus

TLR9 Signaling and Regulatory T-Cells Orchestrate the Immune Response to the Transgene Product in Muscle
Brad E. Hoffman, 1 Mario Cooper, 1 Roland W. Herzog. 1 1 Pediatrics, U of Florida, Gainesville, FL.
Immune responses to gene products are a major concern in gene therapy. For example, in gene replacement therapy for hemophilia, the functional coagulation factor may in fact represent a neo-antigen that can be subject to an adaptive immune response. Thus, the ability to maintain immunological unresponsiveness to the therapeutic protein is a key requirement for successful therapy. The development of effective protocols is dependent upon a deeper understanding of the mechanisms that circumvent the induction of the adaptive response. Advances in the fi eld have suggested that the innate immune response plays an essential role in initiating the process, while activation of immune regulatory pathways can prevent such responses. How innate immunity and immune regulation may be linked has been unclear. Toll-like receptors (TLRs) are a class of proteins that play a signifi cant role in the activation of innate immunity and are believed to primarily drive Th1 immunity. AAV vectors provoke only mild innate immune responses and have thus been considered ideal for therapy by in vivo gene transfer. However, it has recently been demonstrated that the TLR9 pathway is critical for the activation of CD8+ T-cells and antibody responses to the vector capsid and the transgene, potentially leading to the loss of expression. Interestingly, muscle-directed gene transfer of human factor IX (hFIX) results in sustained systemic expression without (or limited) antibody formation in B6 mice if a specifi c AAV serotype and dose is used. In this study, we take advantage of this experimental model to evaluate the interactions between innate mechanisms and CD4+CD25+FoxP3+ Treg-mediated immune tolerance. AAV1-CMV-hFIX (1e11 vg/mouse) containing a TLR9 agonist (CpG-ODN) or vector alone was injected into the muscle of transgenic B6 mice expressing a diphtheria toxin (DT) receptor-fusion protein under the control of the Foxp3 promoter. At 3 & 6 days post gene transfer, groups of mice were administered DT to selectively, but transiently, deplete Foxp3+ Tregs. In contrast to mice that received vector only, transient Treg depletion resulted in complete loss of tolerance as shown by the lack FIX expression and sustained anti-hFIX antibody formation.
Interestingly, when mice received vector combined with TLR9 (but not TLR2) stimulation, there was a transient IgG1 (i.e. Th2like) antibody response that attenuated systemic hFIX expression. However, in the absence of Treg, TLR9 activation failed to induce IgG1 formation and instead drove a substantial CD8+ T cell infi ltration in the muscle, suggesting Th1 immunity. In this case, moderate systemic expression in the absence of anti-hFIX was observed. These results indicate that the integration of TLR9 signaling and Treg function regulates the response to the transgene product in skeletal muscle, with Treg deviating the TLR9-induced response toward Th2. Appearance of viral nucleic acids in mammalian cytoplasm triggers antiviral defense mechanism by activating innate nucleic acids receptors: retinoic acid-inducible gene I (RIG-I) and Toll-like receptors (TLRs). RIG-I is critical in sensing viral RNA and DNA in the cytoplasm of cells. RIG-I belongs to the DExD/H family of helicases, which contains both nucleic acids binding and ATP hydrolysis activity. Activation of RIG-I by binding of non-self RNA present in the cytoplasm invokes antiviral responses including type I interferon (IFN) expression, infl ammasome activation and proapoptotic signaling. Several reports have shown that C-terminal domain of RIG-I recognize distinct RNA patterns: double-stranded (ds) and 5'ppp single-stranded (ss) RNA. These patterns have been believed to be related with the extent of type I IFN immune response in cells. In this study, we have characterized diverse enzyme activities of RIG-I to investigate which enzyme activity of RIG-I is correlated with the extent of immune response in cells. Since the ATPase activity of RIG-I is dependent on the presence and nature of RNA ligands, ATP hydrolysis activity was measured by using several nucleic acid substrates differing in their structure and presence of 5' terminal phosphate. RIG-I exhibited the best ATPase activity for the blunt-end dsRNA with 5'ppp, and the least activity for the ssRNA with 5'OH end. Double-stranded RNA with blunt end is required for stimulation of ATPase activity regardless of 5' terminal phosphate. Nucleic acids binding by RIG-I was also investigated by electrophoresis mobility shift assay and nitrocellulose fi lter binding assay. When the bluntend RNA substrates generated by annealing of two ssRNA strands (47 and 25 nts) were compared for binding to RIG-I, the blunt-end dsRNA containing a longer 5' strand was more favorable for binding. Furthermore, we have observed that ATP hydrolysis signifi cantly weakens stable binding affi nity of RNA ligands to the enzyme. Absence of ATP or nonhydrolyzable ATP analogue showed tighter binding of RNA ligands. We are currently investigating type I IFN response with several RNA ligands transfected into the cells. These results will reveal the important correlation between the innate IFN stimulation and the enzyme activities of RIG-I such as RNA binding affi nity and/or ATPase stimulation extent. HIV-derived, self-inactivating (SIN) lentiviral vectors (LVs), depleted of LTR enhancer and promoter regions, provide an effi cient, versatile and relatively safe gene delivery system. Nevertheless, since LVs integrate preferentially into active genes, they have the potential to de-regulate gene expression at the post-transcriptional level, by interfering with the normal splicing and polyadenylation of primary transcripts. To test this hypothesis, human T cells, myeloid cells and keratinocytes were transduced with a specifi cally designed, "splice trap" LV, and cloned for the expression of a promoter-less GFP gene placed downstream of the constitutive HIV GAG splice acceptor site. Cells were transduced also with SIN-LVs carrying internal GFP expression cassettes or a full human β-globin gene driven by a β-globin promoter and a reduced-size LCR. Cells were randomly cloned and integration sites mapped by LM-PCR in individual clones. Chimeric transcripts were identifi ed by RACE PCR and exon-specifi c RT-PCR. Abnormal, chimeric transcripts were identifi ed in >50% of the LV target genes in all cell types. Semi-quantitative RT-PCR revealed that fusion transcripts were mostly represented at low level compared to constitutively spliced, wild-type transcripts. Fusion transcripts were generated through aberrant splicing caused by the usage of both constitutive and cryptic splice sites located in the viral intron and the U5 portion of the 5' LTR and in the β-globin transcriptional cassette. We have identifi ed a limited set of cryptic splice sites that are responsible for most of the aberrantly spliced transcripts, providing a platform to recoding vector backbones in order to reduce their potential post-transcriptional genotoxicity.
Activities of Nucleic Acid Binding and Stimulation of ATP Hydrolysis by RNA Helicase RIG-I and Activation of Type I Interferon Response
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Integration of Lentiviral Vectors in Human Genes Generates Abnormal Transcripts through the Usage of Constitutive and Cryptic Splice Signals
The RNA Interference Pathway Is Responsible for Silencing of Transgene Expression after Sleeping Beauty Mediated Somatic Integration
Christina Rauschhuber, 1 Anja Ehrhardt. 1 1 Department of Virology, Max von Pettenkofer-Institute, Munich, Germany.
Integrating non-viral vectors based on transposable elements and bacteriophage derived integrases are widely used for genetically engineering mammalian cells in functional genomics and therapeutic gene transfer. For the Sleeping Beauty (SB) transposase, which is the most prominent representative of non-viral integration systems, however, it was demonstrated that convergent transcription driven by the SB transposase inverted repeats (IRs) in eukaryotic cells occurs. This may lead to the formation of double-stranded RNAs potentially presenting targets for the RNA interference (RNAi) machinery and subsequently resulting into silencing of the transgene. Therefore, we aimed at investigating transposition under RNA interference knockdown conditions. Thus, we generated RNAi knockdown HEK293 cell lines by introducing the RNAi suppressor protein P19 derived from the tomato bushy stunt virus to analyze the infl uence of the RNAi pathway. This dimeric protein appears in the cytoplasm and its conformational properties allow the binding and
